Anuh Pharma Ltd
Established in 1960, Anuh Pharma Ltd., a Bulk Drugs Manufacturing Company, is one of the largest manufacturers of Macrolides and Anti-TB products
in India, besides being a major player in Anti-Bacterial, Anti-Malarial, and Corticosteroids. The company is part of the INR 8.5 bn SK Group of Companies, which employs 2000+ people across businesses such as Manufacturing of API's, medicinal chemical and botanical products, Pharma Formulations, Distribution and Logistics (primarily for large MNC brands)
- Market Cap ₹ 1,261 Cr.
- Current Price ₹ 252
- High / Low ₹ 265 / 86.0
- Stock P/E 23.2
- Book Value ₹ 51.2
- Dividend Yield 0.79 %
- ROCE 19.1 %
- ROE 14.5 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 19.0% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 27.6%
Cons
- Company has a low return on equity of 13.9% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
226 | 243 | 266 | 284 | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 640 | |
209 | 225 | 242 | 253 | 289 | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 570 | |
Operating Profit | 17 | 18 | 24 | 31 | 38 | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 70 |
OPM % | 7% | 7% | 9% | 11% | 12% | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 11% |
4 | 2 | 4 | 5 | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 10 | |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 0 |
Depreciation | 1 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 |
Profit before tax | 18 | 18 | 25 | 32 | 38 | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 71 |
Tax % | 29% | 29% | 31% | 31% | 32% | 27% | 29% | 28% | 25% | 26% | 22% | 24% | |
13 | 13 | 18 | 22 | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 54 | |
EPS in Rs | 2.56 | 2.50 | 3.51 | 4.39 | 5.15 | 4.00 | 3.30 | 4.66 | 2.86 | 5.68 | 6.10 | 7.22 | 10.83 |
Dividend Payout % | 36% | 40% | 37% | 27% | 24% | 31% | 42% | 29% | 48% | 26% | 29% | 28% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 17% |
3 Years: | 20% |
TTM: | 28% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 19% |
3 Years: | 35% |
TTM: | 53% |
Stock Price CAGR | |
---|---|
10 Years: | 26% |
5 Years: | 31% |
3 Years: | 23% |
1 Year: | 187% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 13% |
3 Years: | 14% |
Last Year: | 14% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 13 | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 |
Reserves | 65 | 71 | 82 | 97 | 107 | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 232 |
1 | 1 | 0 | 0 | 2 | 0 | 2 | 4 | 45 | 14 | 4 | 1 | 8 | |
49 | 60 | 77 | 67 | 71 | 48 | 57 | 71 | 119 | 128 | 129 | 163 | 135 | |
Total Liabilities | 119 | 136 | 163 | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 400 |
8 | 10 | 12 | 9 | 18 | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 52 | |
CWIP | 3 | 3 | 0 | 0 | 0 | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 1 |
Investments | 33 | 19 | 27 | 43 | 43 | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 80 |
76 | 104 | 124 | 116 | 131 | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 267 | |
Total Assets | 119 | 136 | 163 | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 400 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9 | 2 | 15 | 19 | 16 | 26 | 2 | 7 | 49 | -19 | 29 | 54 | |
2 | 4 | -5 | -12 | -5 | -20 | 2 | 3 | -77 | 52 | -8 | -43 | |
-11 | -6 | -8 | -8 | -9 | -4 | -5 | -7 | 22 | -33 | -19 | -12 | |
Net Cash Flow | 0 | -0 | 2 | -1 | 2 | 2 | -1 | 3 | -5 | 0 | 2 | -2 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 63 | 82 | 102 | 88 | 84 | 100 | 109 | 85 | 96 | 90 | 102 | 118 |
Inventory Days | 24 | 43 | 33 | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 |
Days Payable | 57 | 86 | 102 | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 |
Cash Conversion Cycle | 31 | 39 | 33 | 36 | 42 | 70 | 68 | 61 | 28 | 48 | 62 | 46 |
Working Capital Days | 32 | 45 | 42 | 43 | 51 | 79 | 83 | 70 | 44 | 68 | 70 | 61 |
ROCE % | 26% | 26% | 31% | 33% | 35% | 19% | 14% | 19% | 10% | 16% | 18% | 19% |
Documents
Announcements
-
Compliances-Compliance Certificate For The Financial Ended 31St March, 2024
20h - Compliance Certificate pursuant to Regulation 7(3) of the SEBI (LODR) Regulations, 2015 being received from RTA for the Financial Year ended 31st March, 2024.
-
Under Regulation 40(10) Of The SEBI (LODR) Regulations, 2015
18 Apr - Certificate dated 17th March, 2024 by Sanjay Doshi and Associates, Practicing Company Secretaries for the year ended 31st March, 2024 under Regulation 40(9) of the …
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Compliance Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2024 received from Bigshare Services Private …
- Shareholder Meeting / Postal Ballot-Outcome of AGM 8 Apr
- Announcement Under Regulation 30 (LODR)- Update On Investment In Houban Energy 5 Private Limited A Special Purpose Vehicle, For Solar Project Under Group Captive Model Through Open Access. 4 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
Dec 2017TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
-
Dec 2015TranscriptNotesPPT
-
Sep 2015TranscriptNotesPPT
-
Aug 2015TranscriptNotesPPT
Business Highlights[1]
Anuh Pharma Limited is one of the largest producer of Erythromycin 1st generation salts and pyrazinamide in the world. Anuh Pharma is
also one of the very few to have WHO PQ for sulphadoxine and have applied WHO PQ for Pyrimethamine (Anti malaria).
The Company has over 350 customers in over 57 countries including Europe, Mexico and South Africa